Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a publicly traded pharmaceutical company. It was originally called Microbia, Inc..

Ironwood Pharmaceuticals, Inc
TypePublic
NASDAQ: IRWD (Class A)
Russell 2000 Component
Founded1998
HeadquartersBoston, Massachusetts.
Websitewww.ironwoodpharma.com

Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery.[1][2] In 2002 the company hired John Talley to lead their antifungal drug discovery efforts,[3] which at the time were focused on identifying small molecules that could inhibit fungal invasins,[3][4] along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor,[1] and also Richard Bailey, who had run Monsanto's nutritional business.[2] Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler’s diarrhea.[5][6]

By 2004 the company had raised $99M and was preparing a Phase I trial for linaclotide.[1] By 2006 Microbia was starting to struggle with the different challenges and expenses of drug development, along with its industrial fermentation business and drug discovery efforts, and made the decision to split in two, with "Microbia Precision Engineering" focused on industrial applications led by Bailey and Microbia focused on drug discovery and development.[2] Tate & Lyle invested $7M in the Microbia spinout and took a board seat in 2006.[2] Microbia changed its name to Ironwood in 2008 and shortened the name of the industrial business to Microbia.[7]

By 2009, Ironwood had raised a total of $281M.[2] In early 2010 Ironwood held its IPO, which priced at $11.25 a share, below the target price of $14.[8] Later that year it sold its interests in Microbia to DSM for an undisclosed sum.[9]

Linaclotide (Linzess in the US and Mexico, and as Constella elsewhere),[10] a drug used to treat irritable bowel syndrome with constipation and chronic constipation with no known cause, was approved in the US and Europe in 2012.[11][12] Most of the marketing rights were licensed to Allergan and Astellas.[13][14][15][16]

It was developing a drug called IW-9179 or recanaclotide but abandoned it in 2016.[17]

BNC210 is an anxiolytic that Ironwood licensed and performed R&D on and then abandoned.[18]

In April 2018, the shares of Ironwood Pharmaceuticals closed up more than 10 percent on the news of biotech activist investor, Alex Denner joining its board.[19]

References
  1. Withers, Melissa (September 22, 2004). "Drug hunters". Paradigm Magazine, Whitehead Institute.
  2. Timmerman, Luke (23 February 2009). "Xconomy: Renewables Aren't Just for Biofuels: Microbia Makes Industrial Chemicals a Bit Greener". Xconomy.
  3. Langreth, Robert (June 23, 2003). "The Chemical Cobbler". Forbes.
  4. McCarthy, Alice A. (February 2003). "Microbia" (PDF). Chemistry & Biology. 10 (2): 99–100. doi:10.1016/S1074-5521(03)00031-0. PMID 12618178.
  5. Hornby, PJ (2015). "Drug discovery approaches to irritable bowel syndrome". Expert Opinion on Drug Discovery. 10 (8): 809–24. doi:10.1517/17460441.2015.1049528. PMID 26193876.
  6. "Director profile: Mark Currie, Ph.D." MUSC Foundation for Research Development. Retrieved 15 April 2018.
  7. "Microbia Announces Name Change to Ironwood Pharmaceuticals".
  8. "Ironwood's I.P.O. Disappoints". New York Times DealBook. February 4, 2010.
  9. McBride, Ryan (22 September 2010). "Ironwood Pharmaceuticals Sells Struggling Microbia Subsidiary to Royal DSM". Xconomy.
  10. "Linaclotide - Ironwood Pharmaceuticals". AdisInsight. Retrieved 15 April 2018.
  11. "US label for linaclotide" (PDF). FDA. January 2017. Retrieved 15 April 2018. For label updates see FDA index page for NDA 202811
  12. "UK label: Linaclotide Summary of Product Characteristics". Electronic Medicines Compendium. September 2017. Retrieved 15 April 2018.
  13. Nocera, Joe (9 January 2018). "How Allergan Continues to Make Drug Prices Insane". Bloomberg News.
  14. Jones, Stacy; Burdette, kacy; Wieczner, Jen (July 30, 2015). "From Actavis to Allergan: One pharma company's wild dealmaking journey". Fortune.
  15. "Press release: Allergan Acquires Rights To Ironwoods CONSTELLA® (Linaclotide) From Almirall In More Than 40 Countr". Allergan. 27 October 2015.
  16. "8-K" (PDF). Ironwood. 31 January 2017.
  17. "Recanaclotide - Ironwood Pharmaceuticals". AdisInsight. Retrieved 15 April 2018.
  18. "BNC 210". AdisInsight. Retrieved 15 April 2018.
  19. Tirrell, Meg (2018-04-09). "Biotech activist Alex Denner's next target: Ironwood Pharma". CNBC. Retrieved 2018-05-03.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.